Edwards Lifesciences Corporation
NYSE:EWMedical - Devices
+$0.49 today
- Market cap
- $60.51B
- Beta
- 0.87
- P/E (TTM)
- 46.2
- EPS (TTM)
- $1.89
Volume 3.92M
Average 5.02M
EW Purchases of Investments
Cash used to buy marketable securities and other investments.
Edwards Lifesciences CorporationNYSE: EW
Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026
Purchases of investments dips below year-ago levels
Q2 FY2026 purchases of investments of $564.1M (cash outflow) fell 10.5% year over year, behind the +40.0% change in trailing-twelve-month purchases of investments. Sequentially, it fell 13.7% from the prior quarter. Over 3 fiscal years it compounded at +59.1% a year.
Context
- Purchases of investments amounted to 51.7% of revenue in FY2025, up 34.3 pp from a year earlier.
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.5% toward the trailing-twelve-month pace of +40.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (3.14B) USD
- Year-over-year change
- -231.5%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.14B) | -231.5% |
| FY2024 | 2024-12-31 | (945.8M) | -796.5% |
| FY2023 | 2023-12-31 | (105.5M) | +86.5% |
| FY2022 | 2022-12-31 | (778.9M) | +58.8% |
| FY2021 | 2021-12-31 | (1.89B) | — |
Purchases of Investments vs competitors
How EW compares with its peers on the latest reported figures
- EW's LTM Jun 2026 purchases of investments of $3.08B is the largest of the 6 companies compared; the peer median is $2.1M.
- Its year-over-year change of +40.0% is the 3rd highest of 4, against a peer median of +609.5%.
- Purchases of investments amounts to 47.2% of revenue for EW, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.08B | +40.0% | +59.1% | 47.2% | |
| LTM Sep 2026 | $1.89B | -15.1% | -4.6% | 16.3% | |
| LTM Jun 2026 | $713M | +6026.5% | — | 47.4% | |
| LTM Sep 2026 | $2.1M | +609.5% | +23.9% | 0.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding EW) | $2.1M | +609.5% | +9.6% | 0.1% | |
Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.5B | 1.52B | 1.4B | 4.17B | 1.07B |
| Depreciation & Amortization | 134.8M | 139.6M | 144.9M | 155.2M | 156.6M |
| Deferred Income Tax | (41.4M) | (254.5M) | (272.1M) | (323.4M) | (117.6M) |
| Stock-Based Compensation | 109.3M | 126.8M | 139.4M | 162.3M | 158.1M |
| Change in Working Capital | 145.3M | (421.4M) | (526.3M) | (259.3M) | 154.6M |
| Accounts Receivables | (112.4M) | (84.1M) | (141.2M) | 121.2M | (23M) |
| Inventory | 19M | (213.4M) | (289M) | (256.1M) | 50.7M |
| Accounts Payables | 195.2M | (21.4M) | 146M | 89.5M | 395.1M |
| Other Working Capital | 43.5M | (102.5M) | (242.1M) | (213.9M) | (268.2M) |
| Other Non-Cash Items | (119M) | 105.8M | 7.5M | (3.36B) | 174.1M |
| Operating Cash Flow | 1.73B | 1.22B | 895.8M | 542.3M | 1.6B |
| Capital Expenditures | (329.8M) | (264.8M) | (266.3M) | (252.4M) | (260.2M) |
| Acquisitions (Net) | 329.8M | 0 | (95.2M) | (1.06B) | 0 |
| Purchases of Investments | (1.89B) | (778.9M) | (105.5M) | (945.8M) | (3.14B) |
| Sales of Investments | 529.2M | 1.36B | 715.8M | 857.6M | 2.88B |
| Other Investing Activities | (359.3M) | (63.1M) | (75M) | 3.75B | (195.7M) |
| Investing Cash Flow | (1.72B) | 252.3M | 173.8M | 2.31B | (712.9M) |
| Debt Repayment | (1.8M) | (200K) | (300K) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 174.1M |
| Common Stock Repurchased | (512.8M) | (1.73B) | (879.6M) | (1.16B) | (893.4M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 158.3M | 142.8M | 168.9M | 176.4M | (237.5M) |
| Financing Cash Flow | (356.3M) | (1.58B) | (711M) | (983M) | (956.8M) |
| Effect of Forex Changes | 13.9M | 19.2M | 16.8M | 38.6M | (44.8M) |
| Net Change in Cash | (332.8M) | (94.8M) | 375.4M | 1.91B | (119.3M) |
| Free Cash Flow | 1.4B | 953.4M | 629.5M | 289.9M | 1.34B |
Edwards Lifesciences Corporation
NYSE:EW
Intrinsic Alpha fair value
Locked
Current Price
$105.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.